Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients
Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients
复制标题
DOI：
10.1515/cclm.2009.253
复制
发表时间：
2009-09-01
影响因子：
6.8
通讯作者：
Szmitkowski, Maciej
中科院分区：
文献类型：
--
作者：
Mroczko, Barbara;Groblewska, Magdalena;Szmitkowski, Maciej
背景：胃癌的侵袭和转移依赖于基质金属蛋白酶及其组织抑制物的活性。提示血浆基质金属蛋白酶-9(MMP9)浓度较血清MMP9浓度能更好地预测胃癌的演变。本研究旨在比较血浆和血清金属蛋白酶组织抑制因子-1(TIMP-1)在GC诊断和预后判断中的临床价值。方法：检测73例GC患者和61例正常对照血浆和血清TIMP-1、MMP9和CEA水平。结果：GC患者血浆及血清TIMP-1、MMP9和CEA水平均显著高于正常对照组。血浆TIMP-1的ROC曲线下面积(AUC)(0.961)、诊断敏感性(89%)和准确性(91%)均高于MMP9和CEA。治疗前血浆TIMP-1浓度升高是影响GC患者生存的重要独立预后因素。结论：血浆TIMP-1是一种比血清TIMP-1更好的生物标志物，对GC的诊断和预后有一定的参考价值。临床化学实验室医学2009；47：1133-9。
Background: The invasion and metastases of gastric cancer ( GC) depends on the activities of matrix metalloproteinases and tissue inhibitors of metalloproteinases. It was suggested that the concentration of plasma matrix metalloproteinase-9 (MMP-9) is better than the concentration of serum MMP-9 for prediction of evolution of GC. The aim of the present study was to compare the clinical usefulness of plasma and serum tissue inhibitor of metalloproteinases-1 (TIMP-1) in the diagnosis and prognosis of GC.Methods: Plasma and serum concentrations of TIMP-1, MMP-9 and carcinoembryonic antigen (CEA) were assayed in 73 patients with GC and 61 healthy controls. The diagnostic criteria and prognostic value for the measurands were defined.Results: Plasma and serum TIMP-1, MMP-9 and CEA were significantly higher in GC patients compared with healthy controls. The area under the ROC curve (AUC) (0.961), diagnostic sensitivity (89%) and accuracy (91%) of plasma TIMP-1 were higher than those for MMP-9 and CEA. An increased pre-treatment concentration of plasma TIMP-1 was a significant independent prognostic factor for the survival of patients with GC.Conclusions: These findings suggest that the plasma TIMP-1 is a better biomarker than the serum TIMP-1 and might be useful for the diagnosis of GC and prognosis of patient survival. Clin Chem Lab Med 2009;47:1133-9.